AstraZeneca will pay $125 million upfront for the rights to Nektar"s experimental drugs, NKTR-118 which treats constipation caused by opioid pain drugs, and NKTR-119 which combines NKTR-118 with opioid pain drugs to create a painkiller that doesn"t cause constipation. AstraZeneca will handle the late-stage clinical trials for NKTR-118, as well as manufacturing and marketing while the drug, NKTR-119 is still in early development.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지